Merck’s Clesrovimab (MK-1654), an Investigational Respiratory …
5 days ago · Merck also announced data from a planned interim analysis of the MK-1654-007 trial, a Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV disease.
Merck's Clesrovimab Shows Effectiveness in RSV Prevention for …
1 day ago · Merck's investigational monoclonal antibody, Clesrovimab (MK-1654), has shown promising results in significantly reducing the incidence of respiratory syncytial virus (RSV) disease and related hospitalizations in healthy preterm and full-term infants. Findings presented at IDWeek 2024 highlight Clesrovimab's potential as a crucial preventive ...
With trial win, Merck looks to take on Sanofi, AZ in RSV
5 days ago · With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus. By Kevin Dunleavy Oct 17, 2024 6:00pm. Merck & Co. RSV Beyfortus AstraZeneca. If approved by the ...
Merck Announces Topline Results from Phase 2b/3 Trial of …
Jul 23, 2024 · MK-1654-004 (NCT04767373) is a Phase 2b/3 double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of clesrovimab in healthy preterm and full-term infants. Participants were randomized to receive either a single dose of clesrovimab or placebo.
Merck's RSV antibody for infants effective in reducing some types …
5 days ago · Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
Merck says experimental RSV treatment protected infants in trial
6 days ago · Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s …
Oct 9, 2024 · Merck Underscores Continued Commitment to Fighting Infectious Diseases with More than 40 Data Presentations Across Vaccines, Antibacterials and Antivirals, Including Respiratory Syncytial Virus, Pneumococcal Disease and HIV.
Merck’s Clesrovimab (MK-1654), an Investigational ... - Nasdaq
5 days ago · Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the ...
MSD’s Clesrovimab (MK-1654), an Investigational Respiratory …
5 days ago · In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward ...
What can we help you find? - MSD
Jul 23, 2024 · Participants were randomized to receive either a single dose of clesrovimab or placebo. The primary endpoints include the incidence of participants with RSV-associated medically attended lower respiratory infection (MALRI) from Day 1 (post dose) to Day 150 as compared to placebo and safety.